The United States of America, as Represented by the Secretary, Department of Health and Human Services

US Government as Represented by the Secretary of the Army

Glaxosmithkline Biologicals Sa

Institute for Research in Biomedicine

Humabs Biomed Sa

Other

Janssen Vaccines & Prevention B.v.

Sabin Vaccine Institute

Crucell Holland B.v.

Nancy J Sullivan

Gary J Nabel

Zhi-yong Yang

Zhi-Yong Yang

Cheng Cheng

Anthony Sanchez

Clement Asiedu

Maria Grazia Pau

Stefano Colloca

Alfredo Nicosia

Riccardo Cortese

Jaap Goudsmit

Antonio Lanzavecchia

Davide Corti

Barney S Graham

Virginia Ammendola

Thomas W Geisbert

Bimal Chakrabarti

Julie Ledgerwood

Peter B Jahrling

Sabue Mulangu

Jean-Jacques Muyembe-Tamfun

John Trefry

Daphne Stanley

Robert E Sullivan

John Misasi

Alberto Cagigi

Kendra Leigh

Barncy Graham

Jean Christophe Sabue Mulangu

Antibodies and antigen binding fragments that specifically bind to ebolavirus glycoprotein and neutralize ebolavirus infection are disclosed. Nucleic acids encoding these antibodies, vectors, and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit an ebolavirus infection in a subject.

Neutralizing antibodies to ebola virus glycoprotein and their use

This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).

Chimpanzee adenoviral vector-based filovirus vaccines

Neutralizing antibodies and antigen binding fragments that specifically bind to Ebola virus glycoprotein are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting Ebola virus using the antibodies and antigen binding fragments are disclosed. The antibodies, antigen binding fragments, nucleic acids, and vectors, can be used, for example, to prevent and/or treat Ebola virus infection in a subject.

Neutralizing antibodies to Ebola virus glycoprotein and their use

Provided are recombinant adenovirus vectors (serotype 26 and serotype 35) encoding filovirus antigens. The adenovirus vectors can be used to induce protective immune responses against filovirus infection.

Adenovirus serotype 26 and serotype 35 filovirus vaccines

This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebola virus (EBOV) or Marburg virus (MARV).

Methods for the induction of ebola virus-specific immune responses comprising administering a replication-defective chimpanzee adenovirus vector expressing the ebola virus glycoprotein

The invention is related to a nucleic acid molecule comprising a polynucleotide encoding a modified filovirus glycoprotein (GP) having at least one amino acid change located in a relatively conserved region of said GP that decreases in vitro cytotoxicity and retains immunogenicity when compared to in vitro cytotoxicity and immunogenicity of a wild type filovirus GP, and related modified filovirus GPs, plasmid DNAs, recombinant viruses, adenoviruses, pharmaceutical compositions, vaccine compositions, antibodies that are specifically reactive with the modified filovirus GPs, and related methods of making and using the same.

Nucleic acids encoding modified Ebola virus glycoproteins with diminished cytotoxicity while retaining native antigenic structures

The present invention relates generally to viral vaccines and, more specifically, to filovirus vaccines and methods of eliciting an immune response against a filovirus or disease caused by infection with filovirus.

Development of a preventive vaccine for filovirus infection in primates

Recombinant expression vectors comprising a human codon-optimized marburg virus (MARV) angola glycoprotein gene insert and method of immunization employing said vector

The battery charge indicator provides a color-coded battery status indicator system adapted for attachment to or adjacent the battery compartment on a power tool body. The system includes a first member that is adapted for attachment to the surface of the power tool. The front face of the first member is provided with hook and loop fastener material thereon. A second member has a first face fabricated from green-colored hook and loop fastener material and an opposite, second face fabricated from red-colored hook or loop fastener material. Display of the red-colored face indicates that the battery needs recharging. Display of the green-colored face indicates that the battery is charged.

Battery charge indicator

The present invention relates to genetic vaccines for stimulating cellular and humoral immune responses in humans and other hosts, and, in particular, relates to recombinant viruses that express heterologous antigens of pathogenic viruses, in single dose form.

Method of accelerated vaccination against Ebola viruses

The present invention relates generally to viral vaccines and, more particularly, to filovirus vaccines and methods of eliciting an immune response against a filovirus or disease caused by infection with filovirus.

Growing community of inventors

Kensington, MD, United States of America

Nancy J Sullivan